Saturday, 22 June 2024

Australia's most trusted
source of pharma news

Saturday, 22 June 2024
Listen to this story 

Omico hits impressive milestone

Posted 6 June 2024 AM

An initiative to match people with advanced or incurable cancers, or earlier diagnoses with poor prognosis, to the best treatment for them has reached an important milestone, potentially doubling the overall survival time of those getting matched.

This month cancer genomics initiative PrOSPeCT (Precision Oncology Screening Platform Enabling Clinical Trials) reached a major milestone, with over 5,000 Australians diagnosed with hard-to-treat cancers which have very limited treatment options receiving referrals for free comprehensive genomic profiling of their cancer.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (29)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (7)

Other (20)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.